JPRN-jRCT2061230036进行中（未招募）3 期
An Open-Label, Non-Randomized Study to Assess the Safety and Efficacy of Leniolisib in Japanese Patients With Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Followed By an Open-Label Long-Term Extension
Bradt Jason0 个研究点目标入组 3 人开始时间: 2023年7月4日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •Patient is Japanese.
- •- Patient is male or female and 12 to 75 years of age (inclusive) at the time of the first study procedure.
- •- Patient weighs >=35 kg at baseline.
- •- Patient has a PI3K delta genetic mutation of either the PIK3CD (APDS1) or PIK3R1 (APDS2) gene.
- •- Patient has at least 1 measurable nodal lesion on computed tomography (CT) or magnetic resonance imaging (MRI) scan within 6 months of Screening.
- •- Patient has nodal and/or extranodal lymphoproliferation and clinical findings and manifestations consistent with APDS (e.g., a history of repeated oto-sino-pulmonary infections and/or organ dysfunction consistent with APDS).
- •- At Screening, patient has sitting vital signs (with patient rested for at least 3 minutes) within the following ranges:
- •- Systolic blood pressure, 90-160 mm Hg
- •Diastolic blood pressure, 50-95 mm Hg
- •Pulse rate, 40-100 bpm; up to 110 bpm in adolescents
排除标准
- •- Patient has previous or concurrent use of immunosuppressive medication such as the following:
- •a. A mammalian target of rapamycin inhibitor (e.g., sirolimus, rapamycin, or everolimus) or a PI3K delta inhibitor (selective or non-selective phosphoinositide 3-kinase inhibitors) within 6 weeks prior to first dose.
- •o Short-term use for up to a total of 5 days is allowed but only up to 1 month prior to enrollment in the study.
- •b. B-cell depleters (e.g., rituximab) within 6 months prior to first dose of study treatment.
- •o If patient has received prior treatment with a B-cell depleter, absolute B lymphocyte counts in the blood must have regained normal values.
- •c. Belimumab or cyclophosphamide within 6 months prior to first dose of study treatment.
- •d. Cyclosporine A, mycophenolate, 6-mercaptopurine, azathioprine, or methotrexate within 3 months prior to first dose of study treatment.
- •e. Glucocorticoids above 25 mg prednisone or equivalent per day within 2 weeks prior to first dose of study treatment.
- •f. Other immunosuppressive medications where effects are expected to persist at start of dosing of study treatment.
- •- Patient has had a hematopoietic stem-cell transplant, hematopoietic cell transplant, or bone marrow transplant.
- •- Patient is currently using a medication known to be a strong inhibitor or moderate or strong inducer of isoenzyme cytochrome P450 (CYP)3A if treatment cannot be discontinued or switched to a different medication prior to starting study treatment.
- •- Patient is currently using medications that are metabolized by isoenzyme CYP1A2 and have a narrow therapeutic index (drugs whose exposure response indicates that increases in their exposure levels by the concomitant use of potent inhibitors may lead to serious safety concerns [e.g., Torsades de Pointes]).
- •- Patient had been administered a live vaccine (this includes any attenuated live vaccines) starting from 6 weeks before the anticipated first dose of study treatment, during the treatment period, and up to 7 days after the last dose of leniolisib.
- •- Patient is a pregnant or nursing (lactating) woman, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test.
- •- Patient is a woman of child-bearing potential, defined as a woman physiologically capable of becoming pregnant, unless she is using highly effective methods of contraception during dosing of study treatment and for 30 days after the last study procedure.
研究者
相似试验
进行中（未招募）
不适用
A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%)Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 9.1Level: LLTClassification code 10018937Term: Haemophilia AEUCTR2008-008435-29-CZWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50
进行中（未招募）
1 期
A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A (FVIII:C <1%). - NDSevere hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 9.1Level: LLTClassification code 10018937EUCTR2008-008435-29-ITWyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research & Development50
进行中（未招募）
1 期
The main purpose of this study is to gather information regarding the safety of ReFacto AF, and how well it works (effectiveness) in children with severe Hemophilia A under the age of 12. Approximately 50 subjects, will take part in this study. 25 subjects will be 0-6 years of age and 25 subjects will be 6 to 12 years of age.Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 14.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2008-008435-29-FRWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50
进行中（未招募）
1 期
The main purpose of this study is to gather information regarding the safety of ReFacto AF, and how well it works (effectiveness) in children with severe Hemophilia A under the age of 12. Approximately 50 subjects, will take part in this study. 25 subjects will be 0-6 years of age and 25 subjects will be 6 to 12 years of age.Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 17.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850EUCTR2008-008435-29-BGWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50
进行中（未招募）
1 期
The main purpose of this study is to gather information regarding the safety of ReFacto AF, and how well it works (effectiveness) in children with severe Hemophilia A under the age of 12. Approximately 50 subjects, will take part in this study. 25 subjects will be 0-6 years of age and 25 subjects will be 6 to 12 years of age.Severe hemophilia A (FVIII:C <1%) in male subjects <12 years of age.MedDRA version: 14.1Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2008-008435-29-SEWyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company50